Changzhou Qianhong Biopharma Co Ltd
Changzhou Qianhong Biopharma CO.,LTD manufactures and distributes polysaccharide and protease drugs in China. The company offers heparin sodium, heparin calcium, enoxaparin sodium, dalteparin sodium, nadroparin calcium, pancreatin, heparinoid API, kallidinogenase, and asparaginase. It also provides low molecular weight heparin, compound digestive enzyme preparations, and health products. In addit… Read more
Changzhou Qianhong Biopharma Co Ltd (002550) - Total Assets
Latest total assets as of September 2025: CN¥3.02 Billion CNY
Based on the latest financial reports, Changzhou Qianhong Biopharma Co Ltd (002550) holds total assets worth CN¥3.02 Billion CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Changzhou Qianhong Biopharma Co Ltd - Total Assets Trend (2007–2024)
This chart illustrates how Changzhou Qianhong Biopharma Co Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Changzhou Qianhong Biopharma Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Changzhou Qianhong Biopharma Co Ltd's total assets of CN¥3.02 Billion consist of 59.8% current assets and 40.2% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 15.5% |
| Accounts Receivable | CN¥297.48 Million | 10.5% |
| Inventory | CN¥426.81 Million | 15.1% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥225.92 Million | 8.0% |
| Goodwill | CN¥11.14 Million | 0.4% |
Asset Composition Trend (2007–2024)
This chart illustrates how Changzhou Qianhong Biopharma Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Changzhou Qianhong Biopharma Co Ltd's current assets represent 59.8% of total assets in 2024, a decrease from 65.1% in 2007.
- Cash Position: Cash and equivalents constituted 15.5% of total assets in 2024, down from 29.1% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 7.0% of total assets, an increase from 4.0% in 2007.
- Asset Diversification: The largest asset category is inventory at 15.1% of total assets.
Changzhou Qianhong Biopharma Co Ltd Competitors by Total Assets
Key competitors of Changzhou Qianhong Biopharma Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Changzhou Qianhong Biopharma Co Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Changzhou Qianhong Biopharma Co Ltd generates 0.54x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, Changzhou Qianhong Biopharma Co Ltd generates $ 12.58 in net profit.
Changzhou Qianhong Biopharma Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 11.83 | 8.32 | 5.35 |
| Quick Ratio | 9.50 | 6.21 | 4.27 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.77 Billion | CN¥ 1.35 Billion | CN¥ 1.27 Billion |
Changzhou Qianhong Biopharma Co Ltd - Advanced Valuation Insights
This section examines the relationship between Changzhou Qianhong Biopharma Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.51 |
| Latest Market Cap to Assets Ratio | 0.26 |
| Asset Growth Rate (YoY) | 2.3% |
| Total Assets | CN¥2.83 Billion |
| Market Capitalization | $739.78 Million USD |
Valuation Analysis
Below Book Valuation: The market values Changzhou Qianhong Biopharma Co Ltd's assets below their book value (0.26 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Changzhou Qianhong Biopharma Co Ltd's assets grew by 2.3% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Changzhou Qianhong Biopharma Co Ltd (2007–2024)
The table below shows the annual total assets of Changzhou Qianhong Biopharma Co Ltd from 2007 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.83 Billion | +2.33% |
| 2023-12-31 | CN¥2.77 Billion | -1.42% |
| 2022-12-31 | CN¥2.81 Billion | +11.86% |
| 2021-12-31 | CN¥2.51 Billion | +2.31% |
| 2020-12-31 | CN¥2.45 Billion | -16.44% |
| 2019-12-31 | CN¥2.93 Billion | -7.68% |
| 2018-12-31 | CN¥3.18 Billion | +4.40% |
| 2017-12-31 | CN¥3.04 Billion | +0.34% |
| 2016-12-31 | CN¥3.03 Billion | +7.09% |
| 2015-12-31 | CN¥2.83 Billion | +22.61% |
| 2014-12-31 | CN¥2.31 Billion | +11.83% |
| 2013-12-31 | CN¥2.07 Billion | +7.21% |
| 2012-12-31 | CN¥1.93 Billion | +4.00% |
| 2011-12-31 | CN¥1.85 Billion | +237.85% |
| 2010-12-31 | CN¥548.53 Million | +2.75% |
| 2009-12-31 | CN¥533.87 Million | +36.28% |
| 2008-12-31 | CN¥391.74 Million | +35.76% |
| 2007-12-31 | CN¥288.56 Million | -- |